Observational studyScientific reports2019
Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients.
Observational study in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial.Blood advances · 2024Trial
- Evaluation of hydroxyurea effect in patients with sickle cell disease: A prospective observational study.Indian journal of pharmacology · 2026Observational
- Circulating Monocytes Contribute to Erythrocyte Clearance in Polycythemia Vera.International journal of molecular sciences · 2025Article
- Trained immunity causes myeloid cell hypercoagulability.Science advances · 2025Article
- Monocyte-red blood cell crosstalk supports clearance and heme metabolism in sickle cell anemia.Frontiers in immunology · 2025Article
- Dynamics of neutrophil phenotype and function in sickle cell disease.Frontiers in immunology · 2025Article
- Review
- Children with sickle cell disease: are they protected from serious COVID-19?Frontiers in pediatrics · 2024Article
- Hemolysis dictates monocyte differentiation via two distinct pathways in sickle cell disease vaso-occlusion.The Journal of clinical investigation · 2023Article
- Proinflammatory state promotes red blood cell alloimmunization in pediatric patients with sickle cell disease.Blood advances · 2023Article
- In-Depth Immunological Typization of Children with Sickle Cell Disease: A Preliminary Insight into Its Plausible Correlation with Clinical Course and Hydroxyurea Therapy.Journal of clinical medicine · 2022Article
- Anti-inflammatory cytokines in sickle cell disease.Molecular biology reports · 2022Review
- Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation.EClinicalMedicine · 2022Article
- Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.Cancers · 2021Review
- COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.Cytokine & growth factor reviews · 2021Review
- COVID-19 in Saudi Patients With Sickle Cell Disease: A Retrospective Multi-Center Study.Cureus · 2021Article
- Sickle cell disease and COVID-19: Susceptibility and severity.Pediatric blood & cancer · 2021Review
- Haematological abnormalities in children with sickle cell disease and non-severe malaria infection in western Kenya.BMC infectious diseases · 2021Article
- Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection.Blood advances · 2021Article
- Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
Sickle cell anemia (SCA) is a hemolytic disease in which vaso-occlusion is an important pathophysiological mechanism. The treatment is based on hydroxyurea (HU), which decreases leukocyte counts and increases fetal hemoglobin synthesis. Different cell types are thought to contribute to vaso-occlusion. Nevertheless, the role of monocytes subsets remains unclear. We investigated frequencies of monocytes subsets in blood and their response to HU therapy, testing their ability to express pro-inflammatory molecules and tissue factor (TF). We identified major changes in monocyte subsets, with classical monocytes (CD14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.